Q-omics provides the consensus-scored WIPI1 profile across patient tissues and cancer cell-line models. WIPI1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WIPI1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, WIPI1 protein abundance shows 20,384 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRP, and GBM as cancer lineages where WIPI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WIPI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WIPI1 survival associations across molecular data types. WIPI1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WIPI1 RNA expression–survival associations across cancer types. High WIPI1 expression shows unfavorable associations in UVM, BLCA, MESO, STAD, LGG and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WIPI1 RNA expression.
This table summarizes WIPI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WIPI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WIPI1 shows lower tumor expression in THCA and higher tumor expression in KIRP, BLCA, LIHC, LUAD and CHOL. The KIRP box plot shows higher WIPI1 RNA expression in tumor versus normal tissue (log2 FC = +1.040, t-test p < 0.001).
This table shows molecular features associated with WIPI1 in patient tissues and cancer cell lines. In patient samples, WIPI1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WIPI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
